A new study published in Annals of Allergy, Asthma & Immunology evaluated the effectiveness of a 16-day desensitization protocol in the non-immediate hypersensitivity reactions (HRs) induced by lenalidomide.This study entailed the initiation of a protocol with 1/100thof the daily-prescribed dose of lenalidomidein milligrams of the culprit drug. Subsequently, the doses were slowly increased, in order to complete the procedure in 16 days. Demographic and clinical features of patients were further appraised.Overall, 10 patients (mean age was 64.7±10.8 years) were successfully desensitized to lenalidomide. The mean reaction time was 7.3±3.9 days in the history and the reaction types were delayed urticaria in 4; eczematous rash in 3; and maculopapular eruptions in 3. The desensitization was successfully completed in 16 days in 9 patients. However, in 1, maculopapular eruptions developed on the 11th day and the patient was treated with corticosteroids. Thereafter, the previous tolerated dose was repeated for a longer duration and the regime was completed with a slower dose increment; the targeted dose was achieved in 35 days.From the results, it was concluded that the 16-day desensitization protocol seemed safe and effective in the non-immediate type desensitization hypersensitivity reactions caused by lenalidomide.